CMV infection

Trends, clinical presentations, and treatment

Miguel Madariaga, Andre C Kalil

Research output: Contribution to journalReview article

Abstract

The incidence of cytomegalovirus (CMV) disease has decreased dramatically as a result of the use of HAART in HIV-infected patients and the use of antiviral prophylaxis in solid organ transplant (SOT) recipients. In patients with HIV infection, the retina is still the organ most commonly affected by CMV, whereas in SOT recipients, the transplanted organ is the most common site of infection. The identification of CMV by histopathology is the most definitive diagnostic finding. Ganciclovir remains the mainstay of treatment. High-dose acyclovir, valacyclovir, and ganciclovir are used for CMV prophylaxis. Valganciclovir has been approved for prophylaxis in kidney, kidney-pancreas, and heart transplant recipients who have donor-positive/recipient-negative CMV serostatus. The combination of foscarnet and ganciclovir may be used to treat ganciclovir-resistant CMV infection in SOT recipients and CMV CNS infection in HIV-infected patients.

Original languageEnglish (US)
Pages (from-to)519-538
Number of pages20
JournalInfections in Medicine
Volume24
Issue number12
StatePublished - Dec 1 2007

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Ganciclovir
valacyclovir
Transplants
HIV
Foscarnet
Kidney
Therapeutics
Acyclovir
Highly Active Antiretroviral Therapy
HIV Infections
Antiviral Agents
Retina
Pancreas
Tissue Donors
Transplant Recipients
Incidence
Infection

Keywords

  • Antiviral prophylaxis
  • CMV infection
  • HIV/AIDS
  • Retinitis
  • Transplantation

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

CMV infection : Trends, clinical presentations, and treatment. / Madariaga, Miguel; Kalil, Andre C.

In: Infections in Medicine, Vol. 24, No. 12, 01.12.2007, p. 519-538.

Research output: Contribution to journalReview article

@article{da73fecf65c54dec86b2e62a9d5e253b,
title = "CMV infection: Trends, clinical presentations, and treatment",
abstract = "The incidence of cytomegalovirus (CMV) disease has decreased dramatically as a result of the use of HAART in HIV-infected patients and the use of antiviral prophylaxis in solid organ transplant (SOT) recipients. In patients with HIV infection, the retina is still the organ most commonly affected by CMV, whereas in SOT recipients, the transplanted organ is the most common site of infection. The identification of CMV by histopathology is the most definitive diagnostic finding. Ganciclovir remains the mainstay of treatment. High-dose acyclovir, valacyclovir, and ganciclovir are used for CMV prophylaxis. Valganciclovir has been approved for prophylaxis in kidney, kidney-pancreas, and heart transplant recipients who have donor-positive/recipient-negative CMV serostatus. The combination of foscarnet and ganciclovir may be used to treat ganciclovir-resistant CMV infection in SOT recipients and CMV CNS infection in HIV-infected patients.",
keywords = "Antiviral prophylaxis, CMV infection, HIV/AIDS, Retinitis, Transplantation",
author = "Miguel Madariaga and Kalil, {Andre C}",
year = "2007",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
pages = "519--538",
journal = "Infections in Medicine",
issn = "0749-6524",
publisher = "CMP Healthcare Media LLC",
number = "12",

}

TY - JOUR

T1 - CMV infection

T2 - Trends, clinical presentations, and treatment

AU - Madariaga, Miguel

AU - Kalil, Andre C

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The incidence of cytomegalovirus (CMV) disease has decreased dramatically as a result of the use of HAART in HIV-infected patients and the use of antiviral prophylaxis in solid organ transplant (SOT) recipients. In patients with HIV infection, the retina is still the organ most commonly affected by CMV, whereas in SOT recipients, the transplanted organ is the most common site of infection. The identification of CMV by histopathology is the most definitive diagnostic finding. Ganciclovir remains the mainstay of treatment. High-dose acyclovir, valacyclovir, and ganciclovir are used for CMV prophylaxis. Valganciclovir has been approved for prophylaxis in kidney, kidney-pancreas, and heart transplant recipients who have donor-positive/recipient-negative CMV serostatus. The combination of foscarnet and ganciclovir may be used to treat ganciclovir-resistant CMV infection in SOT recipients and CMV CNS infection in HIV-infected patients.

AB - The incidence of cytomegalovirus (CMV) disease has decreased dramatically as a result of the use of HAART in HIV-infected patients and the use of antiviral prophylaxis in solid organ transplant (SOT) recipients. In patients with HIV infection, the retina is still the organ most commonly affected by CMV, whereas in SOT recipients, the transplanted organ is the most common site of infection. The identification of CMV by histopathology is the most definitive diagnostic finding. Ganciclovir remains the mainstay of treatment. High-dose acyclovir, valacyclovir, and ganciclovir are used for CMV prophylaxis. Valganciclovir has been approved for prophylaxis in kidney, kidney-pancreas, and heart transplant recipients who have donor-positive/recipient-negative CMV serostatus. The combination of foscarnet and ganciclovir may be used to treat ganciclovir-resistant CMV infection in SOT recipients and CMV CNS infection in HIV-infected patients.

KW - Antiviral prophylaxis

KW - CMV infection

KW - HIV/AIDS

KW - Retinitis

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=39749109370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749109370&partnerID=8YFLogxK

M3 - Review article

VL - 24

SP - 519

EP - 538

JO - Infections in Medicine

JF - Infections in Medicine

SN - 0749-6524

IS - 12

ER -